Zynex (NASDAQ:ZYXI) Issues Q1 2025 Earnings Guidance

Zynex (NASDAQ:ZYXI) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of -0.300- for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $30.0 million-, compared to the consensus revenue estimate of $53.5 million.

Zynex Trading Down 2.4 %

NASDAQ ZYXI opened at $7.00 on Wednesday. The firm has a market cap of $222.92 million, a PE ratio of 46.67 and a beta of 0.81. Zynex has a 1-year low of $4.36 and a 1-year high of $13.19. The stock has a 50-day moving average of $7.72 and a 200-day moving average of $8.02. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.11). Zynex had a net margin of 2.49% and a return on equity of 13.05%. During the same period in the prior year, the company posted $0.04 earnings per share. As a group, sell-side analysts forecast that Zynex will post 0.2 EPS for the current year.

Analysts Set New Price Targets

ZYXI has been the topic of a number of research analyst reports. HC Wainwright reduced their price target on Zynex from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday. Royal Bank of Canada lowered Zynex from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $11.00 to $5.50 in a research report on Wednesday. Finally, LADENBURG THALM/SH SH downgraded Zynex from a “buy” rating to a “neutral” rating in a report on Wednesday.

Insider Buying and Selling at Zynex

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total value of $76,800.00. Following the transaction, the chief financial officer now directly owns 19,738 shares of the company’s stock, valued at approximately $151,587.84. This represents a 33.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 30,000 shares of company stock worth $227,100. 52.13% of the stock is owned by corporate insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.